clarithromycin

clarithromycin is a lipid of Polyketides (PK) class. Clarithromycin is associated with abnormalities such as Helicobacter Pylori Infection, Infection, Coinfection, Gastritis and Peptic Ulcer. The involved functions are known as Point Mutation, Increased Sensitivy, Bacterial resistance, urease activity and Mutation. Clarithromycin often locates in Blood, Gastric mucosa, Biopsy sample, Respiratory System and Entire gastrointestinal tract. The associated genes with clarithromycin are Genes, rRNA, rRNA Operon, Genome, HM13 gene and GDF15 gene. The related lipids are 9,11-linoleic acid, Steroids, Lysophosphatidylcholines, Lipopolysaccharides and 4-hydroxycholesterol. The related experimental models are Mouse Model, Knock-out and Experimental Pneumococcal Meningitis.

Cross Reference

Introduction

To understand associated biological information of clarithromycin, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.

What diseases are associated with clarithromycin?

clarithromycin is suspected in Infection, Helicobacter Pylori Infection, Pneumonia, Respiratory Tract Infections, PARKINSON DISEASE, LATE-ONSET, Community acquired pneumonia and other diseases in descending order of the highest number of associated sentences.

Related references are mostly published in these journals:

Disease Cross reference Weighted score Related literature
Loading... please refresh the page if content is not showing up.

Possible diseases from mapped MeSH terms on references

We collected disease MeSH terms mapped to the references associated with clarithromycin

MeSH term MeSH ID Detail
Chlamydial Pneumonia D061387 2 associated lipids
Sacroiliitis D058566 1 associated lipids
Plaque, Atherosclerotic D058226 7 associated lipids
Acute Kidney Injury D058186 34 associated lipids
Upper Extremity Deep Vein Thrombosis D056824 1 associated lipids
Leprosy, Paucibacillary D056005 2 associated lipids
Extensively Drug-Resistant Tuberculosis D054908 1 associated lipids
Buruli Ulcer D054312 1 associated lipids
Immune Reconstitution Inflammatory Syndrome D054019 1 associated lipids
Renal Insufficiency D051437 8 associated lipids
Desulfovibrionaceae Infections D045824 5 associated lipids
Chlamydophila Infections D023521 4 associated lipids
Epilepsy, Partial, Motor D020938 1 associated lipids
Central Nervous System Protozoal Infections D020808 3 associated lipids
Neurotoxicity Syndromes D020258 34 associated lipids
Genetic Predisposition to Disease D020022 24 associated lipids
alpha 1-Antitrypsin Deficiency D019896 3 associated lipids
Tooth, Nonvital D019553 2 associated lipids
Gingival Overgrowth D019214 7 associated lipids
Carcinoma, Lewis Lung D018827 22 associated lipids
Cryptogenic Organizing Pneumonia D018549 3 associated lipids
Ventricular Dysfunction, Left D018487 33 associated lipids
Soft Tissue Infections D018461 2 associated lipids
Pneumonia, Bacterial D018410 16 associated lipids
Cardiovascular Abnormalities D018376 2 associated lipids
Tuberculosis, Multidrug-Resistant D018088 6 associated lipids
Cytomegalovirus Retinitis D017726 2 associated lipids
Community-Acquired Infections D017714 8 associated lipids
Soft Tissue Injuries D017695 2 associated lipids
Periodontal Attachment Loss D017622 7 associated lipids
Kleine-Levin Syndrome D017593 1 associated lipids
Cutaneous Fistula D017577 1 associated lipids
Pityriasis Rosea D017515 3 associated lipids
Dermatitis, Phototoxic D017484 4 associated lipids
Skin Diseases, Bacterial D017192 8 associated lipids
Liver Failure, Acute D017114 11 associated lipids
IgA Deficiency D017098 2 associated lipids
AIDS-Related Opportunistic Infections D017088 9 associated lipids
Common Variable Immunodeficiency D017074 4 associated lipids
Meningitis, Bacterial D016920 6 associated lipids
Angiomatosis, Bacillary D016917 2 associated lipids
Gram-Negative Bacterial Infections D016905 16 associated lipids
Ureaplasma Infections D016869 5 associated lipids
Empyema, Pleural D016724 2 associated lipids
Still's Disease, Adult-Onset D016706 2 associated lipids
Purpura, Thrombocytopenic, Idiopathic D016553 4 associated lipids
Bronchial Hyperreactivity D016535 15 associated lipids
Helicobacter Infections D016481 21 associated lipids
Bacteremia D016470 9 associated lipids
Prosthesis-Related Infections D016459 7 associated lipids
Lymphoma, T-Cell, Cutaneous D016410 4 associated lipids
Eye Infections, Bacterial D015818 3 associated lipids
Eye Infections D015817 1 associated lipids
Eye Injuries, Penetrating D015807 2 associated lipids
Leprosy, Lepromatous D015440 2 associated lipids
Leprosy, Borderline D015439 3 associated lipids
Discitis D015299 2 associated lipids
Mycobacterium avium-intracellulare Infection D015270 4 associated lipids
Sexually Transmitted Diseases, Bacterial D015231 5 associated lipids
Wound Infection D014946 12 associated lipids
Whooping Cough D014917 6 associated lipids
Uveitis, Anterior D014606 11 associated lipids
Urticaria D014581 13 associated lipids
Urination Disorders D014555 9 associated lipids
Urinary Tract Infections D014552 11 associated lipids
Urethritis D014526 9 associated lipids
Ureteral Obstruction D014517 10 associated lipids
Ureteral Diseases D014515 3 associated lipids
Typhoid Fever D014435 2 associated lipids
Tuberculosis, Spinal D014399 1 associated lipids
Tuberculosis, Pulmonary D014397 18 associated lipids
Tuberculosis, Ocular D014392 1 associated lipids
Tuberculosis, Avian D014379 2 associated lipids
Tuberculosis D014376 20 associated lipids
Tooth Discoloration D014075 7 associated lipids
Tenosynovitis D013717 3 associated lipids
Syphilis D013587 6 associated lipids
Synovitis D013585 15 associated lipids
Surgical Wound Infection D013530 7 associated lipids
Stomach Ulcer D013276 75 associated lipids
Stomach Neoplasms D013274 24 associated lipids
Stomach Diseases D013272 7 associated lipids
Sporotrichosis D013174 3 associated lipids
Splenic Diseases D013158 5 associated lipids
Skin Ulcer D012883 6 associated lipids
Skin Neoplasms D012878 12 associated lipids
Skin Diseases, Infectious D012874 7 associated lipids
Sinusitis D012852 9 associated lipids
Shock, Septic D012772 11 associated lipids
Serositis D012700 1 associated lipids
Scrub Typhus D012612 3 associated lipids
Rosacea D012393 13 associated lipids
Rodent Diseases D012376 4 associated lipids
Rickettsia Infections D012282 5 associated lipids
Rhabdomyolysis D012206 9 associated lipids
Radiation Injuries D011832 14 associated lipids
Pyelonephritis D011704 5 associated lipids
Psychoses, Substance-Induced D011605 7 associated lipids
Psychophysiologic Disorders D011602 3 associated lipids
Psoriasis D011565 47 associated lipids
Per page 10 20 50 100 | Total 242

PubChem Associated disorders and diseases

What pathways are associated with clarithromycin

There are no associated biomedical information in the current reference collection.

PubChem Biomolecular Interactions and Pathways

Link to PubChem Biomolecular Interactions and Pathways

What cellular locations are associated with clarithromycin?

Related references are published most in these journals:

Location Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What functions are associated with clarithromycin?


Related references are published most in these journals:

Function Cross reference Weighted score Related literatures

What lipids are associated with clarithromycin?

Related references are published most in these journals:

Lipid concept Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What genes are associated with clarithromycin?

Related references are published most in these journals:


Gene Cross reference Weighted score Related literatures

What common seen animal models are associated with clarithromycin?

Mouse Model

Mouse Model are used in the study 'Inflammation provoked by Mycoplasma pneumoniae extract: implications for combination treatment with clarithromycin and dexamethasone.' (Hirao S et al., 2011), Mouse Model are used in the study 'Tolerance and pharmacokinetic interactions of rifabutin and clarithromycin in human immunodeficiency virus-infected volunteers.' (Hafner R et al., 1998), Mouse Model are used in the study 'Clarithromycin attenuates mastectomy-induced acute inflammatory response.' (Chow LW et al., 2000) and Mouse Model are used in the study 'In vitro and in vivo influence of adjunct clarithromycin on the treatment of mucoid Pseudomonas aeruginosa.' (Bui KQ et al., 2000).

Knock-out

Knock-out are used in the study 'Intrinsic macrolide resistance in Mycobacterium smegmatis is conferred by a novel erm gene, erm(38).' (Nash KA, 2003).

Experimental Pneumococcal Meningitis

Experimental Pneumococcal Meningitis are used in the study 'Failure of treatment for chronic Mycobacterium abscessus meningitis despite adequate clarithromycin levels in cerebrospinal fluid.' (Maniu CV et al., 2001).

Related references are published most in these journals:

Model Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

NCBI Entrez Crosslinks

All references with clarithromycin

Download all related citations
Per page 10 20 50 100 | Total 7636
Authors Title Published Journal PubMed Link
Auw-Hädrich C et al. [Clarithromycin for monotherapy of B-cell MALT lymphoma?]. 2013 Ophthalmologe pmid:24231914
Rezvanian E and Watson NF Kleine-levin syndrome treated with clarithromycin. 2013 J Clin Sleep Med pmid:24235906
Cosme A et al. Usefulness of antimicrobial susceptibility in the eradication of Helicobacter pylori. 2013 Clin. Microbiol. Infect. pmid:22512623
Srivastava S et al. Therapeutic drug management: is it the future of multidrug-resistant tuberculosis treatment? 2013 Eur. Respir. J. pmid:24293417
Gui J et al. [Drug sensitivity analysis of Mycobacterium chelonae and Mycobacterium abscessus and evaluation of Etest for susceptibility testing]. 2013 Zhonghua Jie He He Hu Xi Za Zhi pmid:24252731
Formanoy E et al. Tenosynovitis of the right hand. Mycobacterium kansasii. 2013 Neth J Med pmid:24394739
Chen K et al. Low dose macrolide administration for long term is effective for otitis media with effusion in children. 2013 Auris Nasus Larynx pmid:22673738
Herath SC and Poole P Prophylactic antibiotic therapy for chronic obstructive pulmonary disease (COPD). 2013 Cochrane Database Syst Rev pmid:24288145
Zhu D et al. Synthesis of 4″-O-desosaminyl clarithromycin derivatives and their anti-bacterial activities. 2013 Bioorg. Med. Chem. Lett. pmid:24139585
Nasa M et al. Sequential therapy versus standard triple-drug therapy for Helicobacter pylori eradication: a randomized study. 2013 Indian J Gastroenterol pmid:24158898
Kim SY et al. Comparative study of Helicobacter pylori eradication rates with 5-day quadruple "concomitant" therapy and 7-day standard triple therapy. 2013 J. Clin. Gastroenterol. pmid:22647826
Fagoonee S et al. Efficacy of cefixime-based triple therapy for Helicobacter pylori eradication: a retrospective study. 2013 Panminerva Med pmid:24088806
Gisbert JP et al. Second-line therapy with levofloxacin after failure of treatment to eradicate helicobacter pylori infection: time trends in a Spanish Multicenter Study of 1000 patients. 2013 J. Clin. Gastroenterol. pmid:22647827
Piso RJ et al. Coverage of atypical pathogens for hospitalised patients with community-acquired pneumonia is not guided by clinical parameters. 2013 Swiss Med Wkly pmid:24089030
Schafranek L et al. Clarithromycin enhances dasatinib-induced cell death in chronic myeloid leukemia cells, by inhibition of late stage autophagy. 2013 Leuk. Lymphoma pmid:22656271
Yonezawa H et al. Impact of Helicobacter pylori biofilm formation on clarithromycin susceptibility and generation of resistance mutations. 2013 PLoS ONE pmid:24039906
Gysel M et al. Torsades de pointes following clarithromycin treatment. 2013 Expert Rev Cardiovasc Ther pmid:24147515
Megraud F et al. Helicobacter pylori resistance to antibiotics in Europe and its relationship to antibiotic consumption. 2013 Gut pmid:22580412
[Clarithromycin therapy for patients with cystic fibrosis: a randomized controlled trial]. 2013 Jpn J Antibiot pmid:24930240
Wang S et al. A supra-monolayer nanopattern for organic nanoparticle array deposition. 2013 ACS Appl Mater Interfaces pmid:23480527
Morse AL et al. A randomized controlled trial comparing sequential with triple therapy for Helicobacter pylori in an Aboriginal community in the Canadian North. 2013 Can. J. Gastroenterol. pmid:24340314
Pan W et al. Effects of clopidogrel and clarithromycin on the disposition of sibutramine and its active metabolites M1 and M2 in relation to CYP2B6*6 polymorphism. 2013 Xenobiotica pmid:22830954
Schmidt BJ and Hermansen MN [Late debut of neonatal pneumonia caused by Chlamydia trachomatis]. 2013 Ugeskr. Laeg. pmid:23428270
Tsukanov VV et al. [Helicobacter pylori eradication: current status]. 2013 Ter. Arkh. pmid:23653944
Sierra F et al. Pilot study: miscellaneous therapy is highly successful for Helicobacter pylori eradication. 2013 Aliment. Pharmacol. Ther. pmid:23656465
Radouane N et al. [Generalized chromomycosis caused by Phialophora verrucosa]. 2013 Ann Dermatol Venereol pmid:23466152
Otsuka SH Severe hypoglycemia from Helicobacter pylori triple-drug therapy and insulin detemir drug interaction. 2013 Pharmacotherapy pmid:23471710
Jiang JW et al. Synthesis and antibacterial evaluation of a novel series of 10-hydroxyl ketolide derivatives. 2013 Bioorg. Med. Chem. Lett. pmid:23591116
Odagiri T et al. Design, synthesis, and biological evaluations of novel 7-[7-amino-7-methyl-5-azaspiro[2.4]heptan-5-yl]-8-methoxyquinolines with potent antibacterial activity against respiratory pathogens. 2013 J. Med. Chem. pmid:23409972
Haas K [Reply]. 2013 Ophthalmologe pmid:24377112
Kale-Pradhan PB et al. The role of antimicrobials in Crohn's disease. 2013 Expert Rev Gastroenterol Hepatol pmid:23445237
Pasipanodya JG and Gumbo T Drug concentration monitoring in Mycobacterium avium lung disease: problems with methods and conclusions. 2013 Am. J. Respir. Crit. Care Med. pmid:23457368
Sasaki H et al. Ten-year trend of the cumulative Helicobacter pylori eradication rate for the 'Japanese eradication strategy'. 2013 Digestion pmid:24356705
Yakoob J et al. Low rate of recurrence of Helicobacter pylori infection in spite of high clarithromycin resistance in Pakistan. 2013 BMC Gastroenterol pmid:23433429
Yuan Y et al. Optimum duration of regimens for Helicobacter pylori eradication. 2013 Cochrane Database Syst Rev pmid:24338763
Amin M et al. Anti-Helicobacter pylori and urease inhibition activities of some traditional medicinal plants. 2013 Molecules pmid:23434867
Ogata SK et al. High Helicobacter pylori resistance to metronidazole and clarithromycin in Brazilian children and adolescents. 2013 J. Pediatr. Gastroenterol. Nutr. pmid:23403439
Morgan DR et al. Risk of recurrent Helicobacter pylori infection 1 year after initial eradication therapy in 7 Latin American communities. 2013 JAMA pmid:23403682
Bustamante-Rengifo JA et al. In vitro effect of amoxicillin and clarithromycin on the 3' region of cagA gene in Helicobacter pylori isolates. 2013 World J. Gastroenterol. pmid:24106405
Shallom SJ et al. New rapid scheme for distinguishing the subspecies of the Mycobacterium abscessus group and identifying Mycobacterium massiliense isolates with inducible clarithromycin resistance. 2013 J. Clin. Microbiol. pmid:23804391
Greupink R et al. Semi-mechanistic physiologically-based pharmacokinetic modeling of clinical glibenclamide pharmacokinetics and drug-drug-interactions. 2013 Eur J Pharm Sci pmid:23806476
Kim SG et al. [Guidelines for the diagnosis and treatment of Helicobacter pylori infection in Korea, 2013 revised edition]. 2013 Korean J Gastroenterol pmid:23954956
Park CW et al. Advanced spray-dried design, physicochemical characterization, and aerosol dispersion performance of vancomycin and clarithromycin multifunctional controlled release particles for targeted respiratory delivery as dry powder inhalation aerosols. 2013 Int J Pharm pmid:23820131
Yoshida S et al. Further isolation of Mycobacterium abscessus subsp. abscessus and subsp. bolletii in different regions of Japan and susceptibility of these isolates to antimicrobial agents. 2013 Int. J. Antimicrob. Agents pmid:23850022
Yu Q et al. Treatment of pulmonary mucosa-associated lymphoid tissue lymphoma with clarithromycin. 2013 Chin. Med. J. pmid:23786961
Dabirmoghaddam P et al. The efficacy of clarithromycin in patients with severe nasal polyposis. 2013 Acta Med Iran pmid:23852839
Chen PR and Tan SY [The treatment outcomes of 21 cases of rapidly growing mycobacteria related pulmonary disease]. 2013 Zhonghua Jie He He Hu Xi Za Zhi pmid:23856140
Seyedmajidi S et al. Penbactam for Helicobacter pylori eradication: a randomised comparison of quadruple and triple treatment schedules in an Iranian population. 2013 Arab J Gastroenterol pmid:23622801
Kate V et al. Sequential therapy versus standard triple-drug therapy for Helicobacter pylori eradication: a systematic review of recent evidence. 2013 Drugs pmid:23625272
Kato H et al. Addition of clarithromycin to lenalidomide/low-dose dexamethasone was effective in a case of relapsed myeloma after long-term use of lenalidomide. 2013 Ann. Hematol. pmid:23625297
Bolhuis MS et al. Clinical validation of the analysis of linezolid and clarithromycin in oral fluid of patients with multidrug-resistant tuberculosis. 2013 Antimicrob. Agents Chemother. pmid:23689722
Seddik H et al. Sequential therapy versus standard triple-drug therapy for Helicobacter pylori eradication: a prospective randomized study. 2013 Eur. J. Clin. Pharmacol. pmid:23695545
Kwak HM et al. The efficacy of cefazolin plus macrolide (erythromycin or clarithromycin) versus cefazolin alone in neonatal morbidity and placental inflammation for women with preterm premature rupture of membranes. 2013 Placenta pmid:23465535
Liang JH et al. Synthesis, antibacterial activity and docking of 14-membered 9-O-(3-arylalkyl) oxime 11,12-cyclic carbonate ketolides. 2013 Eur J Med Chem pmid:23202851
Delavenne X et al. A semi-mechanistic absorption model to evaluate drug-drug interaction with dabigatran: application with clarithromycin. 2013 Br J Clin Pharmacol pmid:23210726
Duman DG et al. Saccharomyces boulardii ameliorates clarithromycin- and methotrexate-induced intestinal and hepatic injury in rats. 2013 Br. J. Nutr. pmid:23279717
Bessa LJ et al. Helicobacter pylori free-living and biofilm modes of growth: behavior in response to different culture media. 2013 APMIS pmid:23237527
Qvist T et al. First report of lung transplantation in a patient with active pulmonary Mycobacterium simiae infection. 2013 Transplant. Proc. pmid:23267789
Fiorini G et al. Culture-based selection therapy for patients who did not respond to previous treatment for Helicobacter pylori infection. 2013 Clin. Gastroenterol. Hepatol. pmid:23267869
Kute VB et al. Bronchiolitis obliterans organizing pneumonia (BOOP) after renal transplantation. 2013 Int Urol Nephrol pmid:22547135
Vu DH et al. Troubleshooting carry-over of LC-MS/MS method for rifampicin, clarithromycin and metabolites in human plasma. 2013 J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. pmid:23353809
Kim SG et al. Helicobacter pylori eradication on iatrogenic ulcer by endoscopic resection of gastric tumour: a prospective, randomized, placebo-controlled multi-centre trial. 2013 Dig Liver Dis pmid:23333104
Lim JH et al. Clinical outcomes of two-week sequential and concomitant therapies for Helicobacter pylori eradication: a randomized pilot study. 2013 Helicobacter pmid:23305083
Dumpis U et al. Assessment of antibiotic prescribing in Latvian general practitioners. 2013 BMC Fam Pract pmid:23311389
Huang CW et al. Synergistic activities of tigecycline with clarithromycin or amikacin against rapidly growing mycobacteria in Taiwan. 2013 Int. J. Antimicrob. Agents pmid:23312605
Kawai Y et al. Therapeutic efficacy of macrolides, minocycline, and tosufloxacin against macrolide-resistant Mycoplasma pneumoniae pneumonia in pediatric patients. 2013 Antimicrob. Agents Chemother. pmid:23459497
Thomas M et al. Periprosthetic atypical mycobacterial infection in breast implants: a new kid on the block! 2013 J Plast Reconstr Aesthet Surg pmid:23122691
Pandey SK et al. Antimalarial interaction of quinine and quinidine with clarithromycin. 2013 Parasitology pmid:23137860
Lahbabi M et al. Sequential therapy versus standard triple-drug therapy for Helicobacter pylori eradication: result of the HPFEZ randomised study. 2013 Clin Res Hepatol Gastroenterol pmid:23168228
Darwish KM et al. RP-HPLC/pre-column derivatization for analysis of omeprazole, tinidazole, doxycycline and clarithromycin. 2013 J Chromatogr Sci pmid:23081968
Chodkiewicz HM and Cohen PR Erythrasma: successful treatment after single-dose clarithromycin. 2013 Int. J. Dermatol. pmid:23046434
Lin KJ et al. Safety of macrolides during pregnancy. 2013 Am. J. Obstet. Gynecol. pmid:23254249
Jouneau S et al. Clarithromycin stops lung function decline in airway-centered interstitial fibrosis. 2013 Respiration pmid:23095475
Secka O et al. Antimicrobial susceptibility and resistance patterns among Helicobacter pylori strains from The Gambia, West Africa. 2013 Antimicrob. Agents Chemother. pmid:23263004
Simoens S et al. Preventing COPD exacerbations with macrolides: a review and budget impact analysis. 2013 Respir Med pmid:23352223
Mueck W et al. Co-administration of rivaroxaban with drugs that share its elimination pathways: pharmacokinetic effects in healthy subjects. 2013 Br J Clin Pharmacol pmid:23305158
Seneviratne K and Herieka E A rifampicin-resistant Mycobacterium marinum infection in a newly diagnosed HIV-1 individual. 2013 Int J STD AIDS pmid:23512514
Ogawa K Genetic research about Mycobacterium avium complex. 2013 Kekkaku pmid:23513564
Liang JH et al. Synthesis and antibacterial activity of 9-oxime ether non-ketolides, and novel binding mode of alkylides with bacterial rRNA. 2013 Bioorg. Med. Chem. Lett. pmid:23375796
Karmakar S et al. Hypokalemia: a potent risk for QTc prolongation in clarithromycin treated rats. 2013 Eur. J. Pharmacol. pmid:23567068
Benajah DA et al. Prevalence of Helicobacter pylori and its recurrence after successful eradication in a developing nation (Morocco). 2013 Clin Res Hepatol Gastroenterol pmid:23567104
Bolhuis MS et al. Clarithromycin increases linezolid exposure in multidrug-resistant tuberculosis patients. 2013 Eur. Respir. J. pmid:23520311
Schembri S et al. Cardiovascular events after clarithromycin use in lower respiratory tract infections: analysis of two prospective cohort studies. 2013 BMJ pmid:23525864
Matsumoto T et al. Education and imaging. Gastrointestinal: colonic mucosa-associated lymphoid tissue lymphoma regressed by levofloxacin. 2013 J. Gastroenterol. Hepatol. pmid:23527757
Joosten M et al. Case report: Helicobacter suis infection in a pig veterinarian. 2013 Helicobacter pmid:23551953
Gisbert JP et al. Second-line rescue triple therapy with levofloxacin after failure of non-bismuth quadruple "sequential" or "concomitant" treatment to eradicate H. pylori infection. 2013 Scand. J. Gastroenterol. pmid:23556551
Pilcer G et al. New co-spray-dried tobramycin nanoparticles-clarithromycin inhaled powder systems for lung infection therapy in cystic fibrosis patients. 2013 J Pharm Sci pmid:23568616
Feng Z et al. Dissociative disorder induced by clarithromycin combined with rabeprazole in a patient with gastritis. 2013 J. Int. Med. Res. pmid:23569151
Gokmen T et al. Clarithromycin treatment in preterm infants: a pilot study for prevention of feeding intolerance. 2013 J. Matern. Fetal. Neonatal. Med. pmid:23570248
Metzler K et al. Minimal inhibitory and mutant prevention concentrations of azithromycin, clarithromycin and erythromycin for clinical isolates of Streptococcus pneumoniae. 2013 J. Antimicrob. Chemother. pmid:23169894
Semino-Mora C et al. Antibiotic treatment decreases microbial burden associated with pseudomyxoma peritonei and affects β-catenin distribution. 2013 Clin. Cancer Res. pmid:23743566
Cai M et al. Macrolides inhibit cytokine production by alveolar macrophages in bronchiolitis obliterans organizing pneumonia. 2013 Immunobiology pmid:23199585
Howard ST Recent progress towards understanding genetic variation in the Mycobacterium abscessus complex. 2013 Tuberculosis (Edinb) pmid:24388643
Ergül B et al. The efficacy of two-week quadruple first-line therapy with bismuth, lansoprazole, amoxicillin, clarithromycin on Helicobacter pylori eradication: a prospective study. 2013 Helicobacter pmid:24011287
Gandhi S et al. Calcium-channel blocker-clarithromycin drug interactions and acute kidney injury. 2013 JAMA pmid:24346990
Yu RX et al. Köebner phenomenon induced by cupping therapy in a psoriasis patient. 2013 Dermatol. Online J. pmid:24011324
Abenavoli L et al. Association between non-alcoholic fatty liver disease, insulin resistance and Helicobacter pylori. 2013 Med. Hypotheses pmid:24011768
Nagaoka K et al. Macrolides inhibit Fusobacterium nucleatum-induced MUC5AC production in human airway epithelial cells. 2013 Antimicrob. Agents Chemother. pmid:23380724
Makobongo MO et al. In vitro characterization of the anti-bacterial activity of SQ109 against Helicobacter pylori. 2013 PLoS ONE pmid:23935905
Unai S et al. Sternal wound infection caused by Mycobacterium chelonae. 2013 J Card Surg pmid:23941599